Posted by Michael Wonder on 12 Feb 2025
Lundbeck’s potential treatment amlenetug for multiple system atrophy receives fast track designation from the FDA
12 February 2025 - Lundbeck today announced that amlenetug has received fast track designation from the US FDA.
This designation is based on the outcome of AMULET, the Phase 2 trial, which was presented in March 2024 at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Lisbon, Portugal.
